Using exome sequencing, the team developed a transgenic model with altered orthologs of nine genes and found a combination of drugs that could act as a cancer treatment option.
The firm's "TuMatch" assay integrates patient whole-exome sequencing data and fruit fly models to develop a personalized drug therapy service for cancer patients.
In urothelial cancer, the presence of a gene signature stemming from stromal cells seemed to interfere with anti-PD-1 drug response in tumors with infiltrating T-cells.
